ERBB2 and breast carcinoma: Trastuzumab is clinically administered for patients with HER2-overexpressing metastatic breast cancers, which are defined by strong and complete IHC membranous staining of more than 10% of cells (IHC 3+) and/or in situ hybridization (ISH)-amplified.